Modern medicine stands on a fragile foundation.
Regenerative therapies, vaccines, gene treatments, and cell-based pharmaceuticals all rely on one critical process: cell culture. Yet this essential process depends almost entirely on the manual skills of human technicians—skills that take years to acquire, decades to master, and are now rapidly disappearing.
Across the world, researcher populations are shrinking. In Japan, new research hires have fallen by 30–40% over the past two decades. Demographic decline, reduced funding, and the loss of master-level expertise threaten the very supply chain of future medicine. If we do nothing, the world will face a structural collapse in its ability to deliver regenerative medicine and cell-based therapeutics.
At Transistor Robotics, we exist to confront this challenge head-on. We are building a foundation for the next era of medical infrastructure—one that preserves humanity’s accumulated life-science expertise, strengthens it, and makes it accessible to every nation, every institution, and every patient.
Our vision is simple, but its implications are profound:
A world where regenerative medicine is universally accessible.
A world where vaccines are developed rapidly.
A world where unknown viruses are neutralized early.
A world where cell-based therapeutics reach patients everywhere.
A world where scientific progress accelerates—not slows—when human expertise becomes scarce.
This is not merely a technological ambition. It is a commitment to the future of human health, scientific continuity, and global resilience. Transistor Robotics exists to preserve, accelerate, and globalize humanity’s life-science knowledge—and to establish the next foundation of medical infrastructure for generations to come.
I am grateful to everyone who chooses to walk this path with us. Together, we will build the world that future medicine requires.
Toru FujitaFounder & CEOTransistor Robotics